​

Aquestive Therapeutics (AQST) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Aquestive Therapeutics Revenue Highlights

Latest Revenue (Y)

$57.56M

Latest Revenue (Q)

$13.54M

Main Segment (Y)

Manufacture and Supply Revenue

Main Geography (Y)

UNITED STATES

Aquestive Therapeutics Revenue by Period

Aquestive Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$57.56M13.80%
2023-12-31$50.58M6.09%
2022-12-31$47.68M-6.20%
2021-12-31$50.83M10.87%
2020-12-31$45.85M-12.85%
2019-12-31$52.61M-21.98%
2018-12-31$67.43M0.77%
2017-12-31$66.92M29.22%
2016-12-31$51.78M-

Aquestive Therapeutics generated $57.56M in revenue during NA 2024, up 13.80% compared to the previous quarter, and up 109.41% compared to the same period a year ago.

Aquestive Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$13.54M-32.62%
2024-06-30$20.10M66.76%
2024-03-31$12.05M-8.73%
2023-12-31$13.21M1.57%
2023-09-30$13.00M-1.80%
2023-06-30$13.24M18.92%
2023-03-31$11.13M4.23%
2022-12-31$10.68M-6.81%
2022-09-30$11.46M-13.58%
2022-06-30$13.27M8.11%
2022-03-31$12.27M10.76%
2021-12-31$11.08M-16.63%
2021-09-30$13.29M-13.41%
2021-06-30$15.35M37.97%
2021-03-31$11.12M55.57%
2020-12-31$7.15M-13.45%
2020-09-30$8.26M-61.89%
2020-06-30$21.68M147.29%
2020-03-31$8.77M-46.62%
2019-12-31$16.42M32.22%
2019-09-30$12.42M11.58%
2019-06-30$11.13M-11.98%
2019-03-31$12.64M-24.85%
2018-12-31$16.82M26.81%
2018-09-30$13.27M-4.75%
2018-06-30$13.93M-40.51%
2018-03-31$23.41M91.97%
2017-12-31$12.20M-55.08%
2017-09-30$27.15M143.64%
2017-06-30$11.14M-32.21%
2017-03-31$16.44M-

Aquestive Therapeutics generated $13.54M in revenue during Q3 2024, up -32.62% compared to the previous quarter, and up 102.27% compared to the same period a year ago.

Aquestive Therapeutics Revenue Breakdown

Aquestive Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
Co-Development and Research Fees$1.93M$1.40M$1.29M$1.64M$1.26M
Manufacture and Supply Revenue$39.98M$43.80M$36.38M$35.31M$24.88M
License and Royalty Revenue$15.35M$5.38M$2.35M$5.38M$14.05M
Proprietary Product Sales--$7.66M$8.51M$5.65M
Royalty--$-916.00K$-1.10M-

Aquestive Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Manufacture and Supply Revenue (69.83%), License and Royalty Revenue (26.81%), and Co-Development and Research Fees (3.36%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
License and Royalty Revenue$12.05M$2.16M$1.13M$1.87M$1.10M$1.48M$919.00K$917.00K$376.00K$552.00K$506.00K$380.00K$328.00K$2.36M$373.00K$328.00K$12.93M$426.00K$557.00K-
Manufacture and Supply Revenue$18.79M$10.67M$10.52M$11.00M$11.41M$11.64M$9.76M$8.92M$8.41M$9.87M$9.17M$7.69M$10.45M$10.66M$6.51M$4.80M$5.90M$7.26M$6.92M$14.00M
Co-Development and Research Fees$1.03M$492.00K$403.00K$335.00K$490.00K$124.00K$453.00K$254.00K$395.00K$241.00K$403.00K$218.00K$523.00K$456.00K$394.00K$1.18M----
Manufactured Product, Other-$217.00K------------------
Proprietary Product Sales-------$589.00K$2.28M$2.60M$2.19M$2.79M$1.99M$1.91M$1.58M$682.00K----
Royalty-------$-13.00K$-25.00K-----------

Aquestive Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Manufacture and Supply Revenue (58.95%), License and Royalty Revenue (37.82%), and Co-Development and Research Fees (3.23%).

Aquestive Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 24Dec 23Dec 22Dec 21Dec 20
UNITED STATES$39.93M$37.10M$39.92M$42.86M-
Non-US$17.63M$13.48M$7.76M$7.97M$4.89M
United States----$40.96M

Aquestive Therapeutics's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (69.37%), and Non-US (30.63%).

Quarterly Revenue by Country

CountryDec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Dec 20Dec 19Dec 18Sep 18Jun 18
Non-US$12.99M$3.01M$1.63M$1.47M$3.11M$5.93M$2.97M$2.18M$2.38M$2.01M$1.19M$1.71M$2.76M$2.24M$1.69M$1.81M---
UNITED STATES$18.98M$10.53M$10.43M$11.73M$9.89M$7.31M$8.16M$8.51M$9.08M$11.26M$11.08M$9.37M$10.53M$13.11M-----
United States--------------$5.46M$14.61M$15.51M$12.48M$13.38M

Aquestive Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (59.36%), and Non-US (40.64%).

Aquestive Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
EVOKEvoke Pharma$10.25T$2.65M
ALKSAlkermes$1.56B$378.14M
LNTHLantheus$1.53B$378.73M
AMPHAmphastar Pharmaceuticals$712.81M$188.82M
ANIPANI Pharmaceuticals$614.38M$148.33M
ORGOOrganogenesis$482.04M$115.18M
IRWDIronwood Pharmaceuticals$351.41M$91.59M
DVAXDynavax$277.25M$79.34M
LFCRLifecore Biomedical$128.26M$35.15M
AQSTAquestive Therapeutics$57.56M$13.54M
SHPHShuttle Pharmaceuticals--

AQST Revenue FAQ

What is Aquestive Therapeutics’s yearly revenue?

Aquestive Therapeutics's yearly revenue for 2024 was $57.56M, representing an increase of 13.80% compared to 2023. The company's yearly revenue for 2023 was $50.58M, representing an increase of 6.09% compared to 2022. AQST's yearly revenue for 2022 was $47.68M, representing a decrease of -6.20% compared to 2021.

What is Aquestive Therapeutics’s quarterly revenue?

Aquestive Therapeutics's quarterly revenue for Q3 2024 was $13.54M, a -32.62% decrease from the previous quarter (Q2 2024), and a 4.15% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $20.1M, a 66.76% increase from the previous quarter (Q1 2024), and a 51.79% increase year-over-year (Q2 2023). AQST's quarterly revenue for Q1 2024 was $12.05M, a -8.73% decrease from the previous quarter (Q4 2023), and a 8.25% increase year-over-year (Q1 2023).

What is Aquestive Therapeutics’s revenue growth rate?

Aquestive Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 20.72%, and for the last 5 years (2020-2024) was 25.54%.

What are Aquestive Therapeutics’s revenue streams?

Aquestive Therapeutics's revenue streams in c 24 are Co-Development and Research Fees, Manufacture and Supply Revenue, and License and Royalty Revenue. Co-Development and Research Fees generated $1.92M in revenue, accounting 3.36% of the company's total revenue, up 37.30% year-over-year. Manufacture and Supply Revenue generated $39.98M in revenue, accounting 69.83% of the company's total revenue, down -8.74% year-over-year. License and Royalty Revenue generated $15.34M in revenue, accounting 26.81% of the company's total revenue, up 185.44% year-over-year.

What is Aquestive Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Aquestive Therapeutics was Manufacture and Supply Revenue. This segment made a revenue of $39.98M, representing 69.83% of the company's total revenue.